IPP Bureau
Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
By IPP Bureau - August 12, 2024
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Caplin Point announces completion of unannounced USFDA inspection
By IPP Bureau - August 11, 2024
The inspection was concluded with zero observations
Caplin Point listed on Forbes Asia’s “200 Best under a Billion” for 2024
By IPP Bureau - August 11, 2024
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Zydus receives final approval from USFDA for Valbenazine Capsules
By IPP Bureau - August 11, 2024
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
By IPP Bureau - August 11, 2024
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis
By IPP Bureau - August 11, 2024
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
By IPP Bureau - August 11, 2024
Our centers are performing as expected or even better
Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical
By IPP Bureau - August 11, 2024
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Granules India receives ANDA approval for Trazodone Tablets
By IPP Bureau - August 11, 2024
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Merck's aarogya health program positively impacts communities in Patalganga
By IPP Bureau - August 11, 2024
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb
By IPP Bureau - August 11, 2024
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Allergan Aesthetics drives India’s potential in the global aesthetic market
By IPP Bureau - August 11, 2024
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
By IPP Bureau - August 11, 2024
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years
By IPP Bureau - August 10, 2024
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
By IPP Bureau - August 10, 2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
